Claims
- 1. A compound having the formula:
- 2. A compound in accordance with claim 1, wherein X is N.
- 3. A compound in accordance with claim 1, wherein X is N, and Ar is substituted phenyl.
- 4. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, and R1 is a (C8-C14)acyl group.
- 5. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, and R2 is unsubstituted (C1-C4)alkyl.
- 6. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, and Y is (C2-C5)alkylene.
- 7. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, Y is (C2-C5)alkylene, and Z is dimethylamino.
- 8. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, Y is (C2-C5)alkylene, Z is dimethylamino, and n is 0.
- 9. A compound in accordance with claim 1, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is methyl, Y is ethylene, Z is dimethylamino, and n is 0.
- 10. A compound in accordance with claim 9, wherein said substituted phenyl is selected from the group consisting of 4-fluorophenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-methylphenyl, and 4-bromophenyl.
- 11. A composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
- 12. A composition in accordance with claim 11, wherein X is N.
- 13. A composition in accordance with claim 11, wherein X is N, and Ar is substituted phenyl.
- 14. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, and R1 is a (C8-C14)acyl group.
- 15. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, and R2 is unsubstituted (C1-C4)alkyl.
- 16. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, and Y is (C2-C5)alkylene.
- 17. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, Y is (C2-C5)alkylene, and Z is dimethylamino.
- 18. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is unsubstituted (C1-C4)alkyl, Y is (C2-C5)alkylene, Z is dimethylamino, and n is 0.
- 19. A composition in accordance with claim 11, wherein X is N, Ar is substituted phenyl, R1 is a (C8-C14)acyl group, R2 is methyl, Y is ethylene, Z is dimethylamino, and n is 0.
- 20. A composition in accordance with claim 19, wherein said substituted phenyl is selected from the group consisting of 4-fluorophenyl, 4-methoxyphenyl, 4-chlorophenyl, 4-methylphenyl, and 4-bromophenyl.
- 21. A method of modulating CXCR3 function, said method comprising contacting a CXCR3 protein or truncated form thereof with a CXCR3-modulating amount of a compound having the formula:
- 22. A method of treating a CXCR3-mediated condition or disease in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound having the formula:
- 23. A method in accordance with claim 22, wherein said CXCR3-mediated condition or disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection.
- 24. A method in accordance with claim 22, wherein said CXCR3-mediated condition or disease is multiple sclerosis.
- 25. A method in accordance with claim 22, wherein said administration is oral or intravenous.
- 26. A method in accordance with claim 22, wherein said subject is selected from the group consisting of human, rat, dog, cow, horse, and mouse.
- 27. A method in accordance with claim 22, wherein said subject is human.
- 28. A method in accordance with claim 22, wherein n is 0, Ar is substituted phenyl, R1 is unsubstituted (C5-C15)acyl, R2 is unsubstituted (C1-C4)alkyl, X is N, Y is unsubstituted (C2-C4)alkylene, and Z is selected from the group consisting of methylamino, dimethylamino, ethylamino and diethylamino.
- 29. A method in accordance with claim 22, wherein said CXCR3-mediated disease or condition is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection; n is 0, Ar is substituted phenyl, R1 is unsubstituted (C5-C15)acyl, R2 is unsubstituted (C1-C4)alkyl, X is N, Y is unsubstituted (C2-C4)alkylene, and Z is selected from the group consisting of methylamino, dimethylamino, ethylamino and diethylamino.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application Ser. No. 60/151,212, filed Aug. 27, 1999, the disclosure of which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60151212 |
Aug 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09648329 |
Aug 2000 |
US |
Child |
10279353 |
Oct 2002 |
US |